Despite the significant variability in the expression of these genes among patients, which hinders the identification of a consistent predictive signature, these findings collectively suggest a prominent role for Rho GTPases, particularly the Rac1 pathway, in modulating resistance to 5-FU-based therapies in CRC. The gene discussed is RAC1; the disease is colorectal carcinoma.